Department of Pharmacology, College of Korean Medicine, Sangji University, 83 Sangjidae-gil, Wonju-si, Gangwon-do 26339, Korea.
Central Research Institue of Hawon Pharmaceutical, Jangheung 59338, Korea.
Molecules. 2019 May 2;24(9):1719. doi: 10.3390/molecules24091719.
The aim of this study was to simplify and identify the contents of the herbal formula, HBX-5. This study was carried out to evaluate the therapeutic effects of HBX-6 in a mouse model of benign prostatic hyperplasia (BPH). Based on in vitro, we selected a candidate, reconstituted an experimental agent and investigated the effects on testosterone-induced BPH rats. Cell viability was determined by MTT assay in RWPE-1 and WPMY-1 cells. The expression of androgen receptor (AR) was measured in dihydrotestosterone-stimulated RWPE-1 and WPMY-1 cells. BPH was induced in mice by a subcutaneous injection of testosterone propionate for four weeks. Animals were divided into six groups: Group 1, control mice; Group 2, mice with BPH; Group 3, mice with BPH treated with finasteride; Group 4, mice with BPH treated with 200 mg/kg HBX-5; Group 5, mice with BPH treated with 100 mg/kg HBX-6; and Group 6, mice with BPH treated with 200 mg/kg HBX-6. Changes in prostate weight were measured after treatments, and the thickness of the epithelium was evaluated. The expression levels of proteins associated with prostatic cell proliferation and cell cycle-related proteins were determined. Based on previous reports and in vitro results, we selected and among HBX-5 components and reconstituted the experimental agent, and named it HBX-6. The result represented a new herbal formula, HBX-6 that suppressed the pathological alterations in BPH and showed a marked reduction in proliferation-related protein expression compared to mice with BPH. Our results indicate that HBX-6 has a better therapeutic effect in the BPH murine model than those of HBX-5 and finasteride, suggesting the role of HBX-6 as a new BPH remedial agent.
本研究旨在简化和鉴定 HBX-5 草药配方的内容。本研究旨在评估 HBX-6 在良性前列腺增生 (BPH) 小鼠模型中的治疗效果。基于体外实验，我们选择了一个候选药物，重新构建了一个实验药物，并研究了它对睾丸酮诱导的 BPH 大鼠的影响。在 RWPE-1 和 WPMY-1 细胞中通过 MTT 测定法测定细胞活力。在二氢睾丸酮刺激的 RWPE-1 和 WPMY-1 细胞中测量雄激素受体 (AR) 的表达。通过每周皮下注射丙酸睾丸酮 4 周诱导小鼠发生 BPH。将动物分为 6 组：第 1 组，对照组小鼠；第 2 组，BPH 小鼠；第 3 组，用非那雄胺治疗的 BPH 小鼠；第 4 组，用 200mg/kg HBX-5 治疗的 BPH 小鼠；第 5 组，用 100mg/kg HBX-6 治疗的 BPH 小鼠；第 6 组，用 200mg/kg HBX-6 治疗的 BPH 小鼠。治疗后测量前列腺重量的变化，并评估上皮厚度。测定与前列腺细胞增殖和细胞周期相关蛋白相关的蛋白表达水平。基于先前的报告和体外结果，我们从 HBX-5 成分中选择了 和 ，并重新构建了实验药物，命名为 HBX-6。结果代表了一种新的草药配方 HBX-6，它抑制了 BPH 的病理改变，并显示出与 BPH 小鼠相比增殖相关蛋白表达明显减少。我们的结果表明，HBX-6 在 BPH 小鼠模型中的治疗效果优于 HBX-5 和非那雄胺，表明 HBX-6 作为一种新的 BPH 治疗药物的作用。
Zotero 插件
